What is IEC 62304?

IEC 62304:2006, amended in 2015 and currently under the IEC 62304:2006+AMD1:2015 designation, establishes lifecycle requirements for software that is part of a medical device or that is itself a medical device (Software as a Medical Device, or SaMD). The standard was developed jointly by ISO and IEC and is recognized by FDA, the EU MDR framework, and most other major regulatory jurisdictions.

The standard does not tell developers how to write software. It specifies what processes, activities, and documentation must exist throughout the software lifecycle: from planning and requirements through architecture, detailed design, implementation, testing, maintenance, and problem resolution. The depth of these processes scales with the software’s safety classification.

Software safety classification: the foundation of IEC 62304

IEC 62304 divides medical device software into three safety classes based on the severity of harm that could result from software failure.

Class A: Software whose failure cannot contribute to a hazardous situation, or whose failure can contribute only to a hazardous situation that results in no injury or only negligible injury. Class A software has the lightest documentation requirements under the standard.

Class B: Software whose failure can contribute to a hazardous situation resulting in non-serious injury. Class B requires most of the standard’s process activities but does not require the detailed unit-level testing that Class C demands.

Class C: Software whose failure can contribute to a hazardous situation resulting in serious injury or death. Class C carries the full weight of the standard’s requirements, including unit-level software testing, detailed software architecture documentation, and comprehensive traceability from requirements through testing.

Classification is determined through the risk management process conducted under ISO 14971. Software that controls drug delivery, performs diagnostic calculations that directly drive treatment decisions, or operates implantable devices typically falls into Class C. Administrative software, data archiving tools, and non-decision-support displays often qualify for Class A or B. Misclassification is one of the most common IEC 62304 compliance problems FDA encounters during device inspections.

Core lifecycle processes required by IEC 62304

Software development planning (clause 5.1)

Before development begins, a software development plan must define the lifecycle model to be used, the methods and tools for each activity, the standards to be applied, the approach to integration and testing, the configuration management approach, and the problem resolution process. For Class C software, the plan must also address the approach to software architecture and detailed design. The plan is a living document that must reflect the actual development approach, not a generic template filled in after the fact.

Software requirements analysis (clause 5.2)

All software requirements must be documented. This includes functional requirements, performance requirements, interface requirements, and requirements derived from the risk management process. Requirements must be traceable: every risk control measure that depends on software must appear as a software requirement, and that requirement must be traceable through design, implementation, and verification testing.

A common gap here is that requirements documents describe what the software shall do but omit the performance parameters and failure mode behaviors that determine whether the software meets its safety obligations. FDA reviewers specifically look for requirements that cover how the software behaves under abnormal conditions.

Software architectural design (clause 5.3)

The software architecture must identify all software items (the modular components that make up the system) and their interfaces, and must identify which software items implement security and safety-critical functions. For Class C software, the architecture must be documented in detail sufficient for subsequent detailed design. Architecture documentation must be reviewed and its ability to meet requirements verified before detailed design proceeds.

Software detailed design (clause 5.4)

Required for Class C software (and recommended for Class B), detailed design specifies the internal logic of software units to the level where implementation can proceed without ambiguity. This is the level at which code-to-design traceability is established.

Software unit implementation and verification (clause 5.5)

Each software unit must be implemented according to its detailed design and verified to confirm the implementation is correct. For Class C, unit testing is specifically required. Unit test procedures and results must be documented. For Class B, the verification approach at unit level is more flexible but must still be documented.

Software integration and integration testing (clause 5.6)

Software units are integrated into software items, and software items are integrated into the complete system. Integration testing verifies the interfaces between integrated components work as specified. Test procedures, expected results, and actual results must all be documented. Anomalies discovered during integration testing must enter the problem resolution process.

Software system testing (clause 5.7)

System-level testing verifies that the complete software system meets its requirements under all specified conditions, including boundary conditions and failure modes defined in the risk management process. Test procedures, expected results, and actual results must be documented. For Class C software, regression testing must be performed when the software is modified.

Software release (clause 5.8)

Before release, the manufacturer must ensure that all required activities have been completed and documented, that all known anomalies have been evaluated and either resolved or formally accepted, that the software version is identified in the software configuration record, and that the risk register reflects the final software risk evaluation. A software release record documenting all of this is required.

Software maintenance and problem resolution

IEC 62304 clause 6 covers software maintenance: changes to released software must go through a controlled process that re-evaluates safety classification, conducts impact analysis, and ensures all affected requirements, design elements, and tests are updated and re-verified. This is where organizations with weak change control processes accumulate significant compliance debt: software changes applied outside the formal lifecycle process create documentation gaps that are difficult to reconstruct under regulatory scrutiny.

Clause 9 covers the problem resolution process: a structured feedback loop that captures field problems, software anomalies, and defects, evaluates their safety significance, initiates corrective action where required, and closes the loop with verification that the problem is resolved. This process must be active throughout the product’s market life, not just during development.

Relationship to FDA guidance and QMSR

FDA recognizes IEC 62304 as a consensus standard under the 510(k) and PMA submission process. A declaration of conformance to IEC 62304 in a submission provides reviewers with confidence that the software development lifecycle meets recognized standards without requiring submission of all lifecycle documentation. Submission of the Software Description, Software Level of Concern, and supporting documentation follows FDA’s guidance documents on software in medical devices.

Under the Quality Management System Regulation (QMSR), which took effect in February 2026 and aligns 21 CFR Part 820 with ISO 13485:2016, design and development requirements for software are evaluated under the design controls provisions. IEC 62304 activities map directly to the design planning, design input, design output, design verification, design validation, and design transfer requirements in QMSR and ISO 13485 Section 7.3.

FDA’s 2023 guidance on cybersecurity in medical devices also intersects with IEC 62304: security requirements for software must be captured in the requirements phase, security testing must occur during verification and validation, and the software bill of materials (SBOM) required under the Consolidated Appropriations Act of 2023 depends on the configuration management practices IEC 62304 requires.

Common IEC 62304 deficiencies in FDA inspections

Incorrect safety classification. Manufacturers classify software as Class A or B when the failure mode analysis supports Class C. FDA inspectors are trained to evaluate this, and misclassification found during inspection is a major finding.

Missing traceability. Requirements not traced to test cases. Test cases not traced to requirements. Risk control measures implemented in software but not appearing in the requirements document. Traceability matrices that exist on paper but were not maintained as the software evolved.

Incomplete anomaly management. Known defects in released software that were not formally evaluated for safety significance. A defect log managed informally in a bug tracker that was never reviewed for its relationship to the risk management process.

Inadequate problem resolution process. Post-market complaints and field problems that entered customer service processes but never reached the software problem resolution process for safety evaluation.

How a QMS supports IEC 62304 compliance

IEC 62304 generates a significant volume of controlled documentation: software development plans, requirements specifications, architecture documents, test protocols, test reports, anomaly records, change requests, and release records. Managing this volume in a paper-based or disconnected electronic system creates the traceability gaps that generate FDA findings.

An electronic QMS with design controls, document management, CAPA, and change control modules provides the structured environment these records need. When an anomaly enters the problem resolution process, it links to the relevant software requirement and test record. When a software change is made, the change control workflow ensures that impact analysis, requirement updates, and regression testing are all completed and documented before the change is released.

Cloudtheapp’s platform supports medical device software quality programs with design controls, document control, risk management, CAPA, and change management applications that can be configured to the IEC 62304 lifecycle structure. The 60+ applications available in the Cloudtheapp store give medical device software teams a complete quality infrastructure without building custom systems for each process. To see how Cloudtheapp supports medical device software quality programs, request a demo.

Conclusion

IEC 62304 compliance is not optional for manufacturers of software-embedded or software-as-a-medical-device products. It is the established standard by which regulators evaluate whether a medical device software development program produces reliable, safe output. The companies that execute it well treat it as an engineering discipline rather than a documentation burden: they classify software correctly, maintain traceability throughout the lifecycle, and run a problem resolution process that connects field experience back to the development record. Done with this mindset, IEC 62304 compliance produces better software, fewer recalls, and more predictable regulatory submissions.

This post created by and appeared first on Cloudtheapp

What is ISO 17025?

ISO/IEC 17025:2017 is the globally recognized standard for testing and calibration laboratories. Published by the International Organization for Standardization (ISO) and the International Electrotechnical Commission (IEC), it establishes the requirements a laboratory must meet to demonstrate technical competence and produce valid results.

The standard applies to any organization that performs laboratory testing or calibration, regardless of size or industry. This includes pharmaceutical QC laboratories, food safety testing labs, medical device testing facilities, environmental monitoring labs, and calibration services. In regulated industries, ISO 17025 accreditation is often required by customers, contract agreements, or regulatory bodies as proof that test data is generated under controlled, verified conditions.

The 2017 revision of ISO 17025 introduced a stronger risk-based thinking requirement, updated the management system chapter to align with ISO 9001:2015’s structure, and added explicit requirements for impartiality. Laboratories accredited under the 2005 version had until November 2020 to transition to the 2017 requirements.

How ISO 17025 differs from ISO 9001 and ISO 13485

ISO 9001 and ISO 13485 are quality management system standards. ISO 17025 is a technical competence standard. The distinction matters: ISO 9001 certification tells customers that a company has a documented, controlled quality system. ISO 17025 accreditation tells customers that a laboratory produces technically valid results using verified methods, calibrated equipment, and competent personnel.

A pharmaceutical company can hold ISO 9001 certification for its quality management system and separately pursue ISO 17025 accreditation for its QC laboratory. Medical device manufacturers operating under ISO 13485 may send testing to ISO 17025-accredited external laboratories for third-party verification of product performance. The standards are complementary, not competing.

Structure of ISO 17025:2017

The standard has two main sections: general requirements and resource requirements, followed by process requirements and management system requirements.

General requirements (clauses 4 and 5)

Clause 4 covers impartiality, requiring the laboratory to identify and manage risks to impartiality from internal and external pressures. Financial relationships, personnel conflicts of interest, and commercial relationships with customers all require active impartiality management. Clause 5 covers confidentiality obligations for customer information and test results.

Resource requirements (clause 6)

Clause 6 covers the physical and human resources the laboratory must have and maintain. This includes:

• Personnel competence: documented qualification, training, authorization, and ongoing competency monitoring for all staff who influence laboratory activities
• Facilities and environmental conditions: adequate space, controlled environments, and separation of incompatible activities
• Equipment: calibration status, maintenance records, and protection from unauthorized adjustment. All equipment used for measurement must have calibration traceability to national or international standards
• Metrological traceability: measurement results must be traceable to the International System of Units (SI) through an unbroken chain of calibrations
• Externally provided products and services: controls for purchasing reagents, reference materials, and services that affect laboratory output

Process requirements (clause 7)

Clause 7 is the core of the standard from a technical operations perspective. It covers how the laboratory accepts and reviews customer requests, selects and validates methods, handles samples, ensures measurement uncertainty is understood and reported, ensures data integrity, and reports results.

Method validation is a significant requirement. The laboratory must validate non-standard methods and confirm that standard methods used outside their intended scope are still fit for purpose. Validation parameters include selectivity, linearity, range, precision, bias, and detection limits, depending on the method type. This aligns closely with the analytical method validation requirements in ICH Q2(R1) for pharmaceutical laboratories.

Measurement uncertainty is a requirement that catches many laboratories off guard. ISO 17025 requires the laboratory to identify contributions to measurement uncertainty and estimate their combined effect on reported results. For laboratories previously issuing results without uncertainty statements, this requires a structured uncertainty budget analysis for each method.

The audit trail and data integrity requirements in clause 7.11 require that original observations be recorded at the time they are made, that records be protected from unauthorized change, and that the laboratory retain records in a way that allows reconstruction of the testing activity.

Management system requirements (clause 8)

Clause 8 offers laboratories a choice: implement a management system meeting the full ISO 17025 requirements listed in the clause, or implement and maintain a management system in accordance with ISO 9001 requirements that also satisfies the clause 8 requirements. Most regulated industry laboratories opt for the ISO 17025 management system path and integrate it with their existing ISO 9001 or ISO 13485 QMS.

Management system requirements include document control, control of records, internal audits, management review, risk and opportunity management, improvement actions including corrective actions, and preventive actions. These map closely to the management review and CAPA requirements in other ISO quality standards.

The accreditation process

ISO 17025 accreditation is granted by accreditation bodies that are members of the International Laboratory Accreditation Cooperation (ILAC) network. In the United States, the primary accreditation body for testing and calibration laboratories is ANAB (ANSI National Accreditation Board). In Europe, laboratories may be accredited by bodies such as UKAS (UK), DAkkS (Germany), or COFRAC (France), among others. ILAC mutual recognition arrangements mean that accreditation granted by any ILAC member body is generally accepted by others.

The accreditation process follows a standard sequence:

Application. The laboratory submits an application specifying the scope of accreditation: which test methods, measurement parameters, and matrices it wants accredited. The scope is specific, not a blanket statement. “Water analysis” is not a scope; “determination of nitrates in drinking water by ion chromatography per EPA Method 300.0” is.

Document review. The accreditation body reviews the laboratory’s quality manual, method documentation, equipment records, and personnel qualification records against ISO 17025 requirements. Gaps identified in the document review must be corrected before the on-site assessment.

On-site assessment. Assessors visit the laboratory to observe testing activities, verify that equipment is calibrated and maintained, interview personnel, and review records. Observations are categorized as nonconformances (major or minor) or opportunities for improvement. Major nonconformances must be closed before accreditation is granted.

Proficiency testing. Accreditation bodies require participation in proficiency testing or interlaboratory comparisons for the methods in the accreditation scope. Proficiency testing provides independent evidence that the laboratory produces results consistent with other competent laboratories.

Ongoing surveillance and renewal. Accreditation requires annual surveillance assessments and full reassessment every four years. Any significant change to the laboratory’s scope, methods, or facilities must be reported to the accreditation body.

Common gaps found during ISO 17025 assessments

Based on patterns in accreditation assessment findings across testing laboratories, these are the areas most likely to generate nonconformances:

Incomplete measurement uncertainty budgets. Many laboratories underestimate how many uncertainty contributions must be documented and combined. A complete uncertainty budget for a chromatographic method, for example, includes contributions from calibration standards, instrument precision, sample preparation, environmental conditions, and analyst variability.

Equipment calibration traceability gaps. Calibration certificates that do not demonstrate SI traceability, or that were issued by an accredited calibration body outside the ILAC network, do not satisfy the traceability requirement. Review all calibration providers before an assessment.

Method validation scope mismatches. A laboratory may have validated a method for one matrix and then applied it to a different matrix without documenting additional validation. Assessors look specifically for evidence that the validation covers the actual scope of use.

Personnel competency records incomplete for all activities. ISO 17025 requires competency assessment for sampling, testing, calibration, equipment operation, and result evaluation. Organizations with strong training programs for testing personnel sometimes overlook competency documentation for equipment maintenance and sample receipt roles.

Impartiality management not documented. The 2017 revision’s stronger impartiality requirement catches organizations that have an informal culture of impartiality but no documented process for identifying and managing impartiality risks.

ISO 17025 and regulated industry quality systems

For pharmaceutical laboratories operating under FDA cGMP requirements (21 CFR Part 211) or EU GMP Annex 11, ISO 17025 overlaps significantly with existing requirements but is not identical. FDA does not require ISO 17025 accreditation for in-house pharmaceutical laboratories, but the technical competence requirements of ISO 17025 provide a strong framework for laboratories seeking to demonstrate data integrity and method validation robustness to FDA inspectors.

Contract testing laboratories serving pharmaceutical clients are increasingly expected to hold ISO 17025 accreditation for the methods they perform under contract. The analytical procedures performed by contract labs form part of the pharmaceutical company’s regulatory submission data, and ISO 17025 accreditation provides auditable evidence that those procedures are performed under controlled, verified conditions.

How a QMS supports ISO 17025 compliance

Many of the management system requirements in ISO 17025 clause 8 are directly supported by a modern electronic QMS: document control, audit finding management, corrective action workflows, management review scheduling, and training competency records. For laboratories already operating under ISO 13485 or ISO 9001 using an electronic QMS, extending that system to cover the ISO 17025 management system requirements is often a configuration exercise rather than a new implementation.

Cloudtheapp’s platform includes a laboratory management application alongside document control, audit management, CAPA, and training modules. This means laboratories can manage their ISO 17025 management system requirements, their corrective actions, their internal audit program, and their equipment calibration schedules in a single integrated system, eliminating the disconnected spreadsheets and paper records that create gaps during accreditation assessments. To see how Cloudtheapp supports laboratory quality management programs, request a demo.

Conclusion

ISO 17025 accreditation is the recognized international marker of laboratory technical competence. For testing and calibration laboratories in regulated industries, it provides the structured framework for producing data that customers, regulators, and partners can rely on. The path to accreditation requires rigorous method validation, complete equipment calibration traceability, documented personnel competency, and a management system that supports continuous improvement. Laboratories that invest in building these capabilities find that accreditation assessment becomes a validation of good practice rather than an ordeal.

This post created by and appeared first on Cloudtheapp

Where quality management stands in 2026

The baseline has shifted significantly in the past five years. Cloud-based QMS platforms now hold a dominant market position: cloud and web-based deployments accounted for more than 77% of life sciences quality management software revenue in 2024, according to Grand View Research. The pandemic accelerated adoption by forcing remote audit programs and distributed team collaboration, and those capabilities have become permanent features of how quality programs operate.

The companies that treated that shift as a technology upgrade are now discovering the next gap: their electronic systems capture data correctly, but they still analyze it manually, still react to problems after they occur, and still treat compliance as a documentation exercise rather than an operational signal. The next phase of quality management addresses that gap.

AI in quality management: what is actually happening in 2026

AI in quality management is not one thing. Several distinct applications are at different stages of adoption across the industry.

Document intelligence and classification

Natural language processing tools that can read, classify, and route quality documents have moved from experimental to deployed at a meaningful number of organizations. These tools reduce the manual effort of triaging incoming supplier documentation, classifying deviations, and tagging CAPA records for trend analysis. The accuracy is high enough for routing and classification; human review for regulatory decision-making remains the standard.

Predictive CAPA and deviation trending

QMS platforms with built-in analytics can now identify deviation patterns before they reach a threshold that would trigger a formal investigation. A pharmaceutical facility that generates 40 deviations per month may not notice a gradual increase in a specific product line until the monthly quality review. An AI-assisted trending tool flags the pattern at week two. This shift from monthly reporting to continuous monitoring is the single most operationally significant change AI brings to quality management.

Automated supplier risk scoring

AI-assisted supplier risk tools pull data from internal audit history, CAPA rates, delivery performance, and external sources including FDA warning letter databases and import alert records to generate continuous supplier risk scores. This replaces the static annual supplier review with a dynamic risk signal that updates as new information arrives. Supplier quality management under SQM programs is a natural fit for this capability.

AI-generated regulatory content

Draft generation for SOPs, CAPA investigations, and deviation reports using AI assistance has moved into regulated environments with appropriate controls. The standard emerging across leading organizations is AI-assisted drafting with mandatory human review, edit, and approval before any record is finalized. FDA’s Computer Software Assurance guidance, which emphasizes risk-based testing and human oversight, provides the regulatory framework for this approach.

Key regulatory trends shaping quality through 2026 and beyond

FDA QMSR enforcement ramp-up

FDA’s Quality Management System Regulation (QMSR), which aligned 21 CFR Part 820 with ISO 13485:2016, took effect in February 2026. The transition period has ended and FDA inspectors are now evaluating medical device manufacturers against the full QMSR requirements. The practical implication for quality teams: QMSR requires documented process approach, risk-based thinking embedded throughout the QMS, and management responsibility structured around ISO 13485 Section 5. Companies that updated their quality manuals without updating their actual processes will face findings.

EU MDR post-market surveillance requirements intensifying

The EU MDR post-market surveillance and post-market clinical follow-up requirements are generating significantly more data obligations than the old MDD framework. Notified bodies are increasingly scrutinizing PMCF plans, periodic safety update reports, and summary of safety and clinical performance documents. Quality teams managing EU MDR-regulated devices need electronic systems capable of handling these structured data flows.

China NMPA AI regulation framework

China’s National Medical Products Administration published implementation guidance on AI in pharmaceuticals and medical devices in April 2026, establishing a national AI roadmap for regulated industries. For companies with China market access strategies, understanding how AI-assisted quality processes will be evaluated by NMPA is an emerging requirement.

ICH Q13 continuous manufacturing

ICH Q13, which provides guidance on continuous manufacturing for drug substances and drug products, represents a structural challenge for traditional batch-based quality systems. Quality systems built around batch record review and batch release are not designed for the real-time release testing and continuous process verification that continuous manufacturing requires. Companies building continuous manufacturing capabilities need QMS platforms that can handle real-time data collection and evaluation.

The shift from quality control to quality intelligence

The most significant long-term change in quality management is a conceptual one: the function is moving from quality control (detecting and documenting problems after they occur) to quality intelligence (generating information that prevents problems from occurring and enables faster, better decisions).

Quality intelligence requires three things that most traditional QMS platforms do not provide: real-time data, cross-process analysis, and predictive capability. An electronic QMS that stores records and enforces workflows is a quality control tool. A quality intelligence platform connects data across processes, identifies signals in that data, and surfaces them to decision-makers before they become compliance issues.

This does not mean every quality team needs to build an AI program. It means the platforms they choose should be built on architectures that support data connectivity, built-in analytics, and workflow automation, so that as AI capabilities mature and regulatory frameworks for their use solidify, the infrastructure is already in place.

What quality leaders should prioritize now

Given where the regulatory environment and technology are heading, the quality leaders best positioned for the next five years are those who:

Complete the cloud transition. AI-assisted quality capabilities run on cloud platforms with centralized data. Organizations still running on-premise QMS software or hybrid paper-electronic systems cannot access these capabilities without a platform change.

Establish clean, structured quality data. AI tools are only as useful as the data they analyze. Organizations with inconsistent deviation categorization, informal CAPA documentation, and training records that live in spreadsheets will not benefit from AI trend analysis. Structured data in a well-configured QMS is the prerequisite.

Engage with FDA on AI-assisted processes proactively. FDA’s Computer Software Assurance guidance and the agency’s ongoing AI working groups provide the framework for validated use of AI tools in regulated quality processes. Quality leaders who wait for enforcement to define the boundaries will be behind those who engaged with the guidance early.

Choose platforms built for configurability and growth. The QMS platform decision made today constrains or enables quality capabilities for the next five to ten years. Platforms that require custom code for configuration changes or vendor professional services for every workflow update will not keep pace with the speed at which quality management requirements are evolving.

How Cloudtheapp is built for this evolution

Cloudtheapp’s AI-powered, no-code QMS platform was designed for the direction quality management is heading. The built-in AI configuration engine allows quality teams to translate process requirements into functional applications in natural language, without writing code. The 60+ applications in the Cloudtheapp store cover the full quality, safety, and compliance spectrum, and the built-in analytics layer provides real-time quality performance visibility across all processes.

Because the platform is cloud-native and continuously updated, quality teams access new capabilities as they become available without managing upgrade projects or revalidation cycles. The pre-validated, FDA-compliant architecture means that adding new modules does not restart the computer system assurance process from scratch. To see how Cloudtheapp supports the future of quality management, request a demo.

Conclusion

The future of quality management in life sciences is not a single technology or a single regulatory change. It is a sustained shift in what quality teams do with data, how fast they detect and close problems, and how deeply quality thinking is embedded in operational decisions rather than documented after the fact. The organizations building that capability now, through the right platforms, the right data practices, and the right regulatory literacy, will find the next wave of inspection activity and competitive differentiation considerably more manageable than those who do not.

This post created by and appeared first on Cloudtheapp

What digital transformation actually means for quality teams

In life sciences, digital transformation in quality means replacing disconnected, paper-dependent processes with integrated electronic systems that capture data at the source, automate routine workflows, and give quality leaders real-time visibility across their operations.

That definition sounds straightforward. In practice, it touches every part of a quality management system: document control, training management, CAPA, audits, supplier qualification, deviation management, and management review. Each process has legacy habits, existing documentation, and personnel who have built workflows around the current system. Changing one area without the others creates integration problems that often make things worse before they get better.

According to Grand View Research, cloud and web-based QMS deployments accounted for 77.03% of the life sciences quality management software market revenue in 2024, up from a minority position five years earlier. That shift reflects a genuine change in how quality leaders think about their systems: less on-premise infrastructure to maintain, faster deployment cycles, and better access for distributed teams.

The three most common starting points

Most quality digital transformation projects start in one of three places, depending on what is causing the most immediate pain.

Document control first

Document control is the most common entry point because paper-based document systems are visibly painful: version control errors, distribution failures, training records that cannot be linked to document revisions, and audit preparation that takes weeks. Moving document control to an electronic system produces visible, measurable improvements quickly and builds organizational confidence for subsequent phases.

CAPA and deviation management

For companies facing regulatory pressure, CAPA digitization is often urgent. FDA warning letters frequently cite inadequate CAPA systems, closed CAPAs without verified effectiveness, and lack of trend analysis. An electronic CAPA system that enforces workflow structure, deadlines, and effectiveness checks addresses these citations directly.

Audit management

For organizations with heavy supplier audit programs or upcoming certification audits, moving audit management to an electronic system reduces preparation burden and creates structured records that satisfy auditor requests. Remote audit capability, an increasing requirement in post-pandemic quality programs, requires electronic systems by definition.

Why digital transformation projects in quality fail

Quality digital transformation has a high failure rate not because the technology does not work, but because organizations underestimate the human and process dimensions. McKinsey’s January 2025 analysis of AI and digital adoption in life sciences identified data strategy and organizational change as the top two barriers to realizing the value of digital investments, ahead of technology capability.

Treating it as an IT implementation

When quality digital transformation is run by IT rather than quality leadership, the resulting system is technically functional but practically unused. Configuration decisions get made by people who do not understand the quality workflows, and the system ends up replicating paper processes electronically rather than improving them. Quality leaders must own the configuration requirements, even when IT owns the infrastructure.

Skipping process redesign

Digitizing a broken process produces a broken digital process. The move to an electronic QMS is an opportunity to eliminate redundant steps, clarify ownership, and build in controls that paper systems cannot enforce. Organizations that map their current processes, identify waste, and redesign workflows before configuring the system get significantly more value from the technology.

Underestimating change management

Quality professionals who have worked with paper-based systems for years have strong procedural habits. Training on a new system is necessary but not sufficient. Organizations need structured change management: clear communication about why the change is happening, involvement of end users in configuration decisions, champions within each department, and a feedback loop after go-live that addresses usability problems quickly.

Choosing a platform that cannot grow

Some organizations select a point solution for their most urgent problem, say document control, only to discover it does not integrate with the CAPA or audit system they need next. They end up with multiple disconnected electronic systems that require manual data transfer between them, recreating the integration problems of paper in a digital format.

Regulatory risks specific to digital transitions

The transition period itself carries regulatory risk. While the old system is being wound down and the new system is being rolled out, organizations run dual systems for a period. This creates several risks.

Data migration gaps. Historical records that exist only in the paper system need either migration or a defined retrieval process. FDA inspectors can and do request records from periods before the electronic system went live. Know where those records are and how quickly you can produce them.

Validation obligations. An electronic QMS used in a regulated environment requires computer system validation or, under FDA’s 2022 Computer Software Assurance guidance, a risk-based assurance approach. Validation documentation must be complete before the system goes live for production use. A pre-validated cloud platform reduces this burden significantly compared to an on-premise deployment, but it does not eliminate the obligation entirely.

21 CFR Part 11 compliance. Any system handling electronic records and electronic signatures for FDA-regulated activities must comply with 21 CFR Part 11. This includes audit trail requirements, access controls, and electronic signature authentication. Confirm Part 11 compliance status before selecting any platform.

Training record currency. When processes change as part of a digital transformation, affected SOPs must be revised, employees must be retrained, and training records must reflect the new versions. Quality teams sometimes undercount the training documentation burden that accompanies a system implementation.

The opportunities that justify the effort

Despite the challenges, the quality organizations that complete digital transformations consistently report three categories of improvement that paper systems cannot deliver.

Real-time visibility

Paper-based quality systems are inherently backward-looking: metrics only exist after records are compiled and reported, usually monthly. An electronic QMS produces metrics in real time. Quality leaders can see open CAPAs by age, overdue training by department, and deviation trends by product line without waiting for monthly compilation. This changes how quality decisions get made and how quickly problems get escalated.

Faster audit cycles

Audit preparation that takes two to three weeks with a paper system typically takes two to three days with an electronic system where records are searchable and current. The audit trail is automatic. Document version history is complete. Training records are linked to document revisions. External auditors and regulators get what they ask for faster, which shortens audit duration and reduces the stress that compressed preparation timelines create.

Cross-site consistency

Organizations with multiple manufacturing sites, contract manufacturers, or remote quality teams face a structural disadvantage with paper-based systems: each site develops slightly different interpretations of shared procedures, and quality performance differences across sites are difficult to detect before they surface in an inspection finding. A cloud-based QMS enforces the same process structure, document versions, and training requirements across every site that uses it.

How to sequence a life sciences quality digital transformation

A practical sequence for a mid-size life sciences company:

Phase 1 (months 1 to 3): Document control and training management. These two processes are tightly linked (training completion depends on document revisions) and touch every employee. Getting them right establishes the foundation for everything else.

Phase 2 (months 3 to 6): CAPA, deviations, and nonconformance management. These processes depend on document control being electronic to function properly: CAPA records reference SOPs, and deviations link to batch records and specifications.

Phase 3 (months 6 to 12): Audit management, supplier qualification, and risk management. These are higher-configuration processes that benefit from Phase 1 and 2 data already being in the system.

Phase 4 (months 12+): Advanced modules: management review, objectives and targets, analytics dashboards, and integration with ERP or laboratory systems.

Not every organization follows this sequence. A company facing an imminent supplier audit may need to prioritize audit management in Phase 1. The point is to sequence based on business risk and dependencies, not vendor sales materials.

What a no-code platform changes about the timeline

Traditional enterprise QMS implementations took 12 to 18 months because every configuration required IT involvement, custom code, or vendor professional services. A no-code cloud QMS built for life sciences compresses that timeline significantly by giving quality teams direct control over process configuration.

Cloudtheapp’s platform gives quality operations teams a drag-and-drop configuration environment where workflows, forms, approval chains, and notifications are set without writing code. When a process needs to change, quality teams make the change directly rather than waiting months for an IT change request cycle. This matters enormously during digital transformation, when process refinements in the first 90 days of go-live are common and fast iteration separates successful implementations from stalled ones.

With 60+ pre-built quality and compliance applications available in the Cloudtheapp store, quality teams can deploy a core module in days and configure it to their specific processes before go-live. The pre-validated, FDA-compliant platform covers the computer system assurance burden, freeing quality teams to focus on process design rather than validation documentation. To see how the platform works in a life sciences environment, request a demo.

Conclusion

Digital transformation in life sciences quality is a strategic necessity, not a technology trend. The regulatory environment is more complex, supply chains are more distributed, and the cost of quality failures is higher than it was a decade ago. Paper-based quality systems were not designed for this environment. The organizations building competitive advantage in quality today are not doing so through better paper management. They are doing it through connected data, faster processes, and quality systems that make compliance an output of how work gets done rather than a separate documentation exercise.

This post created by and appeared first on Cloudtheapp

What is a remote audit in life sciences?

A remote audit is a structured quality assessment conducted without physical presence at the site being reviewed. The auditor accesses documentation, observes processes through live video feeds, and interviews personnel via videoconference from a different location.

In life sciences, remote audits apply across several contexts: supplier qualification audits, internal system audits, GCP audits of clinical research sites, and under specific regulatory programs, agency inspections. The International Coalition of Medicines Regulatory Authorities (ICMRA) published a reflection paper in 2021 documenting how agencies across more than 30 countries applied remote inspection methods and most found the approach viable for document-heavy assessments even when physical observation of manufacturing processes remained preferable.

When remote audits work and when they do not

Remote audits are strongest when the audit scope centers on documentation review, quality system structure, and record completeness. They are less suitable when the audit requires direct observation of aseptic technique, cleanroom behavior, or physical equipment verification that a camera cannot fully capture.

Good candidates for remote execution include:

• Supplier qualification audits for software vendors, service providers, and raw material distributors where facility observation is secondary to quality system evaluation
• Internal document control and management review audits
• Follow-up audits to verify corrective action closure after an audit finding
• GCP audits at clinical investigator sites, where the primary evidence is in trial master files and patient records
• FDA Remote Regulatory Assessments (RRAs), a formal mechanism introduced through CDER and CDRH programs post-2020

Audits that typically still require on-site presence include sterile manufacturing facilities, sites with active FDA warning letters, initial supplier qualifications for critical API manufacturers, and any audit involving direct observation of a complex manufacturing process.

Regulatory acceptance: FDA, EMA, and ISO programs

FDA formalized its remote inspection approach through the Remote Regulatory Assessment program. These are not official surveillance inspections; they are a separate mechanism used to gather information about a facility’s quality system. FDA has used RRAs for both CDER and CDRH-regulated facilities and has continued the program beyond the pandemic period.

The EMA and EU national competent authorities documented their remote GMP inspection experiences through the ICMRA reflection paper. Agencies including the MHRA, Health Canada, TGA, and PMDA all reported successful remote inspections for certain site categories, particularly for those with strong compliance histories and mature quality systems.

ISO 19011:2018, the guidelines for auditing management systems, does not prohibit remote auditing. The standard focuses on audit principles, evidence collection, and auditor competence regardless of format. ISO/IEC 17021-1, which governs certification body audits, was updated to formally acknowledge remote audit methods, and most accreditation bodies now accept a hybrid approach where desk reviews occur remotely and physical process observations happen on-site.

Technology requirements for remote audits

The technology stack for a reliable remote audit covers four areas: secure document sharing, live video observation, communication, and audit trail documentation.

Secure document access

Auditors need access to controlled documents without downloading uncontrolled copies. A cloud-based QMS with role-based access lets the auditee grant temporary read-only access to specific document sets: SOPs, batch records, training logs, CAPA records, in a controlled and time-limited way. PDF exports sent over email introduce version control risks and are difficult to revoke. Controlled electronic access is the more defensible approach.

Live video capability

For facility walkthroughs and process observations, stable high-bandwidth video is non-negotiable. Platforms like Zoom or Microsoft Teams support screen sharing alongside live camera feeds. Some organizations deploy smart glasses or portable cameras to give remote auditors a continuous first-person view of the facility. Connection quality at the auditee site is often the limiting factor, particularly for international audits, so pre-audit connectivity tests matter.

Audit documentation tools

Audit checklists, observation logs, and findings should be documented in real time. An integrated audit management application within the QMS lets auditors log observations directly into structured fields during the audit, auto-timestamps entries, and ties findings to the relevant document or process being reviewed.

Best practices for remote audit preparation

Most remote audit failures trace back to inadequate preparation rather than technology problems. These practices reduce that risk.

Align on scope and format before the audit date

A written remote audit plan should confirm what will be reviewed, which personnel will be available, the videoconference platform, document access method, and any physical observation segments. Send this to the auditee at least two weeks in advance.

Test technology 48 hours in advance

Run a full technology rehearsal with the auditee’s team. Test document sharing, video quality, screen share functionality, and backup communication channels. Identify the point of contact at the auditee site who will manage technology issues on audit day.

Request document packages in advance

For document-heavy audits, request pre-read packages 5 to 7 business days before the audit. This lets auditors focus live time on clarifying questions rather than reading SOPs in real time. Define exactly which documents are needed and the preferred access method: controlled electronic access is preferable to email attachments.

Define the on-site escort role

For any physical observation segment, assign a dedicated facility escort whose only job is to operate the camera and navigate the auditor through the facility via video. This person should not be answering audit questions simultaneously.

Conducting the remote audit

Opening meetings follow the same structure as on-site audits: confirm scope, introduce participants, agree on timelines, and explain how findings will be documented. Structured time blocks work better than open-ended exploration in remote settings. A clear agenda with 30- to 45-minute segments, defined document sets per segment, and named subject matter experts for each topic keeps the audit moving.

Process audits conducted remotely require the auditee to walk the auditor through a process using live camera footage while simultaneously making relevant records available for review on a shared screen. This dual-stream approach is the closest remote equivalent of tracing a process physically through a facility.

Closing meetings should summarize preliminary findings verbally before the written audit report. Surprises in a written report that were not discussed in closing create disputes and erode trust in the audit process.

Documentation requirements

Remote audits generate the same documentation obligations as on-site audits: an audit plan, attendance records, evidence reviewed, observations, findings, and a final audit report. The additional requirement in a remote format is documenting the audit method itself, noting that the audit was conducted remotely, which technology was used, any connectivity issues encountered, and whether any scope items were deferred because they could not be adequately assessed remotely.

The audit trail within your QMS should capture when auditors accessed documents, when findings were logged, and when corrective action requests were issued. This creates a defensible, timestamped record that holds up under regulatory scrutiny.

Common challenges and practical solutions

Document access delays. Auditees unfamiliar with granting controlled electronic access sometimes default to sending PDFs by email, creating version control issues. Specify in the audit plan exactly how documents will be shared and confirm the method during the technology rehearsal.

Bandwidth at international sites. Remote audits of facilities in regions with limited internet infrastructure struggle with video quality. Pre-agree a low-bandwidth fallback: the auditee provides a pre-recorded facility walk-through video for physical observations, while live video handles interviews and document review.

Engagement fatigue. Full-day remote audits are harder to sustain than on-site audits. Break them into half-day sessions where scope allows, or structure the day with explicit breaks and clearly timed segments.

Scope gaps from physical limitations. Document clearly in the audit report which items could not be fully assessed remotely and whether a follow-up on-site visit is recommended.

How a cloud QMS supports remote audit programs

Organizations best positioned for remote audits are those running quality operations in a cloud-based QMS. When documents, training records, CAPA logs, and audit findings live in a single system, granting an auditor time-limited read access takes minutes rather than days of document preparation.

Cloudtheapp’s audit management application supports remote audit programs directly: structured audit plans, real-time observation logging, automatic linking of findings to CAPA workflows, and a complete audit trail for every record touched during the audit. Auditors receive scoped access to relevant modules without exposing unrelated quality data, and all access is timestamped and logged automatically.

Quality teams using Cloudtheapp also avoid the document package preparation burden that makes remote audits administratively heavy. When records are already structured, controlled, and searchable in the system, producing evidence for an auditor is a search-and-share operation rather than a document retrieval project. To see how Cloudtheapp supports remote and on-site audit programs, request a demo.

Conclusion

Remote audits are a permanent part of life sciences quality programs, accepted by FDA, EMA, ISO accreditation bodies, and notified bodies for a wide range of audit types. The quality teams that execute them well invest in three areas: a cloud QMS that makes controlled document access straightforward, a clear remote audit protocol that addresses technology and documentation, and trained auditors who adapt their technique to the format rather than treating remote as a degraded version of on-site work. Done well, remote audits extend a quality program’s reach to more suppliers, more sites, and more frequent audit cycles than an on-site-only program can sustain.

This post created by and appeared first on Cloudtheapp